Pro/con clinical debate: Hydroxyethylstarches should be avoided in septic patients by Schortgen, Frédérique et al.
279 COP = colloid osmotic pressure; HES = hydroxyethylstarches.
Available online http://ccforum.com/content/7/4/279
A septic patient is in your intensive care unit and you are
concerned that he is behind on his intravascular volume. For
a variety of reasons you have decided you would like to give
him intravenous colloids. The only colloid available in your
intensive care unit is hydroxyethylstarch.
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Abstract
There are few issues in critical care medicine that have a less clearly defined standard of care than the
intravenous fluid choice for resuscitation. Natural colloids (such as albumin) became popular during the
Second World War when there was a need to develop a portable, easily stored, blood substitute. Early
successes led to widespread use and a multibillion dollar industry. It is not surprising given the large
demand, high costs and potential adverse effects of natural colloids that synthetic colloids have
emerged. In the present article, two groups of clinical investigators remind us of the controversies
surrounding the use of synthetic colloids.
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The scenario
Pro: Yes, hydroxyethylstarches should be avoided in septic patients
Frédérique Schortgenand Laurent Brochard
Capillary leakage during sepsis is a reason for
recommending the use of macromolecules that could
preserve the colloid osmotic pressure (COP). The high cost
of albumin has facilitated the widespread use of
hydroxyethylstarches (HES). Outcome studies on sepsis are
scarce, and the reasons why we should use HES remain
speculative or based on short-term physiological data. The
reason why we should avoid HES is much better
documented. We will briefly describe how uncertain are the
clinical benefits of these products and, by contrast, how
strong is the evidence for numerous adverse effects.
Both crystalloids and colloids have a similar ability to achieve
sufficient volume loading when the volume administered
takes into account the capacity of the solution to remain in
the intravascular space [1]. To achieve an equivalent plasma
volume expansion, a fourfold greater volume of crystalloid
may be needed in comparison with 5% albumin [1].
Maintaining COP by administration of HES could, in theory,
reduce pulmonary oedema. One study including septic
patients found a higher incidence of pulmonary oedema after
crystalloids than after HES [2]. Most clinical results have280
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been disappointing, however, and a meta-analysis showed
that pulmonary oedema occurrence is similar with colloids or
crystalloids [3]. Indeed, in the context of a free course of
macromolecules across a damaged alveolocapillary
membrane, the Starling equation indicates that colloidal
forces can no longer stop fluid shift.
An attractive, although unproven, pharmacological effect of
HES comes from experimental studies suggesting that HES
could improve microcirculation [4]. Clinical studies were
again disappointing. Boldt and colleagues found a better
intramucosal pH in patients receiving HES in comparison
with albumin [5], but two recent studies in septic
hypovolaemic patients showed that HES did not improve
splanchnic circulation whereas gelatins did [6,7].
The case for adverse events secondary to administration of
HES is much stronger and concerns coagulation disorders,
acute renal failure, liver failure and pruritis [8–12]. Initially
shown in a situation of ischaemia reperfusion (i.e. renal
transplant recipients) [8], the nephrotoxicity of
hydroxyethylstarch has been demonstrated in a randomised
study during severe sepsis [9]. In comparison with gelatins,
HES 200kDa/0.6 induced a twofold higher incidence of
acute renal failure.
The adverse effects of HES may depend on the molecular
weight and the degree of substitution (proportion of
hydroxylethyl groups on glucose molecules) [13]. The
conflicting results coming from coagulation studies cast
doubts whether an optimal combination for these two
parameters has yet been found. Comparing HES
200kDa/0.5 and 130kDa/0.4, Jamnicki and colleagues
found the same disturbances in in vitro coagulation tests
[14]. A recent meta-analysis in cardiac surgical patients
showed that postoperative bleeding was more frequent with
HES, whatever the molecular weight, than with albumin [11].
Concerning acute renal failure, no comparative study
supports the hypothesis that the newer compounds are
safer. In a prospective randomised study including 150
postoperative patients with sepsis, a 50% increase in the
serum creatinine was found at day 3 in the
hydroxyethylstarch 200kDa/0.5 group against only a 6%
increase with albumin [15]. This difference was not
significant, but this result again suggests that doing no harm
should be our primary goal.
If the only colloids available are HES, the actual equipoise
regarding efficacy means that we choose crystalloids to
avoid adverse effects on organ function.
Con: No, hydroxyethylstarches should not be avoided in septic patients
Ellen Burnham and Greg S Martin
Fluid exchange across the capillary endothelium obeys
Starling’s Law {V = Kf[(PC – PI) – σ(πC – πI)]}, which
describes the forces governing fluid flux across a
semipermeable membrane, such as the human vasculature
[16]. Hydrostatic pressure and COP (π) are the primary
determinants of fluid flux in this system. When these forces
are in balance, homeostasis between the intravascular and
extravascular fluid compartments is maintained. The
difference in hydrostatic pressure (Pcapillaries – Pinterstitium)
pushes fluid out of the vasculature, while the difference in
COP (πcapillaries – πinterstitium) draws fluid into the
vasculature. The relative effect of oncotic pressure is
modulated by the reflection coefficient (σ), describing the
integrity of the capillary wall in preventing translocation of
proteins.
Colloids were developed as a durable alternative to
crystalloids and blood products for patients requiring fluid
resuscitation. Colloids exist in two general forms: natural and
synthetic. In practical terms, this translates into albumin
versus starches, gelatins, dextrans or combination solutions.
Because of cost differentials, conflicting evidence and the
underemphasis of COP in shock states, the solution of
choice for resuscitating patients is controversial. The
utilisation of a crystalloid solution in volume resuscitation,
especially in situations where patients are hypoproteinemic,
such as sepsis, may promote extravasation of volume out of
the vascular space and into the interstitium, where it is of little
help in rectifying hypotension [1].
Physiologically, the use of resuscitative fluid containing
osmotically active molecules of low molecular weight that
are biodegradable with a moderate halflife would be ideal
in septic patients, who have greater capillary permeability
and, frequently, a low COP. HES are such agents. HES
solutions contain molecules with a wide range of
molecular weights and have an effect on intravascular
volume lasting about 24 hours. In the intravascular
compartment, HES are progressively hydrolysed into
smaller fractions that are ultimately excreted by the
kidneys [4].
Colloidal agents are more efficacious at restoring plasma
volume compared with crystalloids, per unit of fluid given
[1,17]. Furthermore, HES continue to provide volume
expansion even in states of capillary permeability [18].
Investigators have demonstrated that, in hypovolaemic shock,
resuscitation with starches or albumin results in a lower
incidence of pulmonary oedema, compared with crystalloids
[2]. Additionally, maintenance of COP may prevent
complications of critical illness, including refractory acidosis
[19], acute respiratory distress syndrome, prolonged
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In the absence of abnormally high hydrostatic pressure, low
COP does not promote lung fluid accumulation [24].
Whereas a low COP may induce soft tissue oedema, several
effective mechanisms protect against alveolar flooding. Low
COP is rather a marker of severity for capillary leakage and of
the amount of volume needed before acute respiratory
distress syndrome onset. The ability of plasma expanders to
reverse microvascular damages is not limited to starches, or
even to colloids. Similar beneficial effects have been shown
using hypertonic crystalloids [25]. One might not forget that
the best way to reverse low COP and microvascular
damages in sepsis remains early and adequate anti-infectious
treatment.
Con’s response
Ellen Burnham and Greg S Martin
For improving outcomes in critically ill patients with severe
sepsis there is an absence of evidence regarding intravenous
solutions. Colloids have physiologic advantages over
crystalloids, but suffer from higher acquisition costs. In light
of recent evidence specifically regarding HES, advocating
their use in patients with severe sepsis is problematic.
Although HES may be the economic colloids of choice, we
must focus our prescribing choices on patient-centred
outcomes. Association does not indicate causation and, until
clinical trials evaluating appropriate clinical outcomes are
performed, we will continue to deliver imprecise critical care.
Intensivists should prescribe intravenous therapy based upon
patient-specific factors, recognising that newer starches
might obviate the associated risks, which are also absent
with natural colloids.
Apart from being pure volume expanders, HES have specific
pharmacologic properties that may be beneficial in sepsis,
such as lowering the circulating levels of adhesion molecules
[21], and thus potentially reducing endothelial activation and
damage. In septic patients, endogenous vasopressor
production is decreased in patients receiving HES compared
with other colloids [22]. Additionally, HES may exert useful
effects on the microvascular coagulation cascade of these
patients by elevating levels of protein C and protein S [23].
The use of HES as a resuscitative fluid in this patient with
septic shock makes sound physiologic sense, particularly if
COP is already reduced. Experimental data have
demonstrated the efficacy of HES in the restoration of
intravascular volume, and the unique pharmacologic
properties of HES may provide additional benefit. Finally,
prevention of the sequelae from sepsis could neutralise any
acquisition cost associated with colloids.
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